APGE · As filed with the SEC
Apogee Therapeutics balance sheet, by quarter
The statement as Apogee Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED BALANCE SHEETS · USD
| USD | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 105,571,000 | 451,797,000 | 131,549,000 | 107,914,000 | 124,192,000 | 106,916,000 | 141,789,000 | 118,780,000 |
| Marketable securities | 866,355,000 | 608,088,000 | 598,643,000 | 419,375,000 | 381,228,000 | 406,413,000 | 378,864,000 | 407,269,000 |
| Prepaid expenses and other current assets | 19,807,000 | 13,912,000 | 11,166,000 | 12,808,000 | 10,702,000 | 8,202,000 | 9,060,000 | 8,434,000 |
| Total current assets | 991,733,000 | 1,073,797,000 | 741,358,000 | 540,097,000 | 516,122,000 | 521,531,000 | 529,713,000 | 534,483,000 |
| Long-term marketable securities | 321,943,000 | 198,354,000 | 172,730,000 | 61,640,000 | 115,769,000 | 168,106,000 | 210,416,000 | 227,746,000 |
| Property and equipment, net | 4,822,000 | 5,280,000 | 5,688,000 | 6,032,000 | 6,438,000 | 5,679,000 | 1,959,000 | 1,417,000 |
| Right-of-use asset, net | 6,708,000 | 7,707,000 | 8,687,000 | 9,646,000 | 10,586,000 | 11,507,000 | 11,365,000 | 12,126,000 |
| Other non-current assets | 10,607,000 | 8,516,000 | 8,671,000 | 8,744,000 | 8,857,000 | 7,339,000 | 498,000 | 514,000 |
| Total assets | 1,335,813,000 | 1,293,654,000 | 937,134,000 | 626,159,000 | 657,772,000 | 714,162,000 | 753,951,000 | 776,286,000 |
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 3,080,000 | 1,237,000 | 1,221,000 | 376,000 | 5,678,000 | 2,445,000 | 1,071,000 | 2,216,000 |
| Lease liability | 2,365,000 | 3,138,000 | 3,504,000 | 4,079,000 | 4,025,000 | 3,976,000 | 3,234,000 | 2,867,000 |
| Accrued expenses | — | — | — | — | — | — | — | 27,528,000 |
| Accrued expenses and other current liabilities | 32,065,000 | 28,577,000 | 23,181,000 | 29,592,000 | 21,848,000 | 26,539,000 | 24,255,000 | — |
| Total current liabilities | 37,510,000 | 32,952,000 | 27,906,000 | 34,047,000 | 31,551,000 | 32,960,000 | 28,560,000 | 32,611,000 |
| Long-term liabilities: | ||||||||
| Lease liability, net of current | 4,468,000 | 4,909,000 | 5,345,000 | 5,774,000 | 6,820,000 | 7,840,000 | 8,597,000 | 9,273,000 |
| Revenue share liability | 99,231,000 | — | — | — | — | — | — | — |
| Total liabilities | 141,209,000 | 37,861,000 | 33,251,000 | 39,821,000 | 38,371,000 | 40,800,000 | 37,157,000 | 41,884,000 |
| Stockholders' equity: | ||||||||
| Common Stock; $0.00001 par value, 400,000,000 authorized, 75,611,894 issued and 75,339,499 outstanding as of June 30, 2026; 400,000,000 authorized, 69,038,943 issued and 68,401,349 outstanding as of December 31, 2025 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 |
| Additional paid-in capital | 1,918,830,000 | 1,892,411,000 | 1,464,561,000 | 1,077,681,000 | 1,046,066,000 | 1,033,542,000 | 1,021,794,000 | 969,829,000 |
| Accumulated other comprehensive (loss) income | (2,503,000) | (749,000) | 1,080,000 | 1,028,000 | 685,000 | 1,074,000 | 915,000 | 3,270,000 |
| Accumulated deficit | (721,724,000) | (635,870,000) | (561,759,000) | (492,372,000) | (427,351,000) | (361,255,000) | (305,916,000) | (238,698,000) |
| Total stockholders' equity | 1,194,604,000 | 1,255,793,000 | 903,883,000 | 586,338,000 | 619,401,000 | 673,362,000 | 716,794,000 | 734,402,000 |
| Total liabilities and stockholders' equity | 1,335,813,000 | 1,293,654,000 | 937,134,000 | 626,159,000 | 657,772,000 | 714,162,000 | 753,951,000 | 776,286,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.